Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 7/20 | 0.32 |
| ▸ | MMP2 | P08253 | 6/20 | 0.32 |
| ▸ | MMP1 | P03956 | 5/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88565 | 1.00 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL3458099 | 1.00 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| Hydrochloric Acid SCHEMBL76316 | 0.97 | CA2 (0.36) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| Hydrochloric Acid SCHEMBL17392837 | 0.97 | CA2 (0.36) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL2089233 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTPTGS1TP53TSHR | |
| SCHEMBL2089231 | 0.81 | ALDH1A1 (0.36) | ALDH1A1MAPTPTGS1TP53TSHR | |
| SCHEMBL162227 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL18095144 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL18095145 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL28479550 | 0.78 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | PREVECEUTICAL MEDICAL INC (CA) | 2026-01-01 | — | — | US | disclosed |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
| US-20240059740-A1 | CYCLIC PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-02-22 | — | — | US | disclosed |
| EP-4175970-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2023-05-10 | — | — | EP | disclosed |
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| WO-2011107843-A2 | PROCESS FOR THE PREPARATION OF ATAZANAVIR SULFATE SUBSTANTIALLY FREE OF DIASTEREOMERS | LUPIN LIMITED (IN) | 2011-09-09 | — | — | WO | disclosed |
| EP-2262538-A1 | OLIGOMER-AMINO ACID AND OLGOMER-ATAZANAVIR CONJUGATES | Nektar Therapeutics (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009114151-A1 | OLIGOMER-AMINO ACID AND OLGOMER-ATAZANAVIR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | CA2 4611/4885ALDH1A1 4191/4885MAPT 745/4885 |
| US-20240059740-A1 | CYCLIC PEPTIDES AND USES THEREOF | VIP, NGLY1, LNPEP | CA2 1375/4885ALDH1A1 4833/4885MAPT 2310/4885 |
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | CA2 4777/4885ALDH1A1 3850/4885MAPT 1087/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | CA2 4777/4885ALDH1A1 3850/4885MAPT 1087/4885 |
| US-20260001910-A1 | PEPTIDES AND USES THEREOF | MMP3, PEPD, MMP9 | CA2 531/4885ALDH1A1 3511/4885MAPT 2889/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | CA2 3830/4885ALDH1A1 4427/4885MAPT 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.